trending Market Intelligence /marketintelligence/en/news-insights/trending/AnrFYlDPqZMeIeO-G8XZyA2 content esgSubNav
In This List

Affimed's drug combination for Hodgkin lymphoma well-tolerated in phase 1b study

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Affimed's drug combination for Hodgkin lymphoma well-tolerated in phase 1b study

Affimed NV said a combination of its AFM13 drug and Merck & Co. Inc.'s Keytruda was well-tolerated in patients with relapsed or refractory Hodgkin lymphoma in an ongoing phase 1b study.

The combination treatment is being investigated as a salvage therapy for patients who have failed prior standard treatments like brentuximab vedotin.

The early results showed a three-month overall response rate of 83%, compared to the historical overall response rate of Keytruda as a monotherapy of 58% to 63%.

Affimed said the most common side effects observed were infusion-related reactions, nausea, diarrhea, headache, pyrexia and rash.

The preliminary data was presented by Affimed at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.